行情

GLPG

GLPG

Galapagos
NASDAQ

实时行情|Nasdaq Last Sale

183.75
-0.05
-0.03%
盘后: 183.35 -0.4 -0.22% 16:11 11/15 EST
开盘
182.74
昨收
183.80
最高
184.95
最低
182.07
成交量
28.51万
成交额
--
52周最高
192.89
52周最低
85.00
市值
113.84亿
市盈率(TTM)
38.15
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GLPG 新闻

  • RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $158
  • Benzinga.13小时前
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.1天前
  • Is Galapagos NV's (AMS:GLPG) CEO Pay Justified?
  • Simply Wall St..2天前
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.2天前

更多

所属板块

生物技术和医学研究
+1.35%
制药与医学研究
+1.27%

热门股票

名称
价格
涨跌幅

GLPG 简况

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
展开

Webull提供Galapagos NV的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。